Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Cost-effectiveness of point of care smoking cessation interventions in oncology clinics
by
Hewitson, Shelley
, Scoville, Joshua
, Kumar, Eshwar
, Mullen, Kerri A.
, Grant, Alyssa
, Warren, Graham W.
, Hurley, Kelly
, Thavorn, Kednapa
in
Bupropion
/ Bupropion - economics
/ Bupropion - therapeutic use
/ Cancer therapies
/ Cigarette smoking
/ Cost analysis
/ Cost-Benefit Analysis
/ Drug addiction
/ Female
/ Humans
/ Male
/ Middle Aged
/ Neoplasms - economics
/ Neoplasms - therapy
/ Oncology
/ Patients
/ Point-of-Care Systems - economics
/ Smoking cessation
/ Smoking Cessation - economics
/ Smoking Cessation - methods
/ Smoking Cessation Agents - economics
/ Smoking Cessation Agents - therapeutic use
/ Tobacco Use Cessation Devices - economics
/ Varenicline - economics
/ Varenicline - therapeutic use
2024
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost-effectiveness of point of care smoking cessation interventions in oncology clinics
by
Hewitson, Shelley
, Scoville, Joshua
, Kumar, Eshwar
, Mullen, Kerri A.
, Grant, Alyssa
, Warren, Graham W.
, Hurley, Kelly
, Thavorn, Kednapa
in
Bupropion
/ Bupropion - economics
/ Bupropion - therapeutic use
/ Cancer therapies
/ Cigarette smoking
/ Cost analysis
/ Cost-Benefit Analysis
/ Drug addiction
/ Female
/ Humans
/ Male
/ Middle Aged
/ Neoplasms - economics
/ Neoplasms - therapy
/ Oncology
/ Patients
/ Point-of-Care Systems - economics
/ Smoking cessation
/ Smoking Cessation - economics
/ Smoking Cessation - methods
/ Smoking Cessation Agents - economics
/ Smoking Cessation Agents - therapeutic use
/ Tobacco Use Cessation Devices - economics
/ Varenicline - economics
/ Varenicline - therapeutic use
2024
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Cost-effectiveness of point of care smoking cessation interventions in oncology clinics
by
Hewitson, Shelley
, Scoville, Joshua
, Kumar, Eshwar
, Mullen, Kerri A.
, Grant, Alyssa
, Warren, Graham W.
, Hurley, Kelly
, Thavorn, Kednapa
in
Bupropion
/ Bupropion - economics
/ Bupropion - therapeutic use
/ Cancer therapies
/ Cigarette smoking
/ Cost analysis
/ Cost-Benefit Analysis
/ Drug addiction
/ Female
/ Humans
/ Male
/ Middle Aged
/ Neoplasms - economics
/ Neoplasms - therapy
/ Oncology
/ Patients
/ Point-of-Care Systems - economics
/ Smoking cessation
/ Smoking Cessation - economics
/ Smoking Cessation - methods
/ Smoking Cessation Agents - economics
/ Smoking Cessation Agents - therapeutic use
/ Tobacco Use Cessation Devices - economics
/ Varenicline - economics
/ Varenicline - therapeutic use
2024
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Cost-effectiveness of point of care smoking cessation interventions in oncology clinics
Journal Article
Cost-effectiveness of point of care smoking cessation interventions in oncology clinics
2024
Request Book From Autostore
and Choose the Collection Method
Overview
We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care.
A decision analytic model was completed from the healthcare payer's perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA).
The ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC + SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC + SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC + SSM. Both were cost-effective in 100% of 1000 simulations.
Given the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.
Publisher
Nature Publishing Group,Nature Publishing Group UK
This website uses cookies to ensure you get the best experience on our website.